Incyte Corp.
(NASDAQ:INCY) reported better-than-expected second-quarter results on Tuesday and raised its full-year sales guidance after broad-based growth across its commercial portfolio, led by strong demand for Opzelura and its hematology and oncology products.
The biopharmaceutical company reported adjusted earnings of $3.09 per share, beating the analyst consensus estimate of $2.12.
Revenue rose 38% year over year to $1.67 billion, topping the consensus estimate of $1.46 billion.
Total net sales increased 40% to $1.49 billion.
